194 related articles for article (PubMed ID: 7956216)
1. Modulatory influence of oral contraceptives on mammary growth pattern of normal and ovariectomised mice.
Ecavade A; Rao AR
Contraception; 1994 Aug; 50(2):175-83. PubMed ID: 7956216
[TBL] [Abstract][Full Text] [Related]
2. Modulatory influence of oral contraceptive pills Ovral and Noracycline on 3-methylcholanthrene-induced carcinogenesis in the uterine cervix of mouse.
Hussain SP; Rao AR
Jpn J Cancer Res; 1992 Jun; 83(6):576-83. PubMed ID: 1644661
[TBL] [Abstract][Full Text] [Related]
3. Effects of oral contraceptive pills on drug metabolizing enzymes and acid soluble sulfhydryl level in mouse liver.
Hussain SP; Chhabra SK; Rao AR
Biochem Int; 1991 Dec; 25(5):973-84. PubMed ID: 1804114
[TBL] [Abstract][Full Text] [Related]
4. Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial.
Notelovitz M; Kitchens CS; Khan FY
Am J Obstet Gynecol; 1992 Nov; 167(5):1255-61. PubMed ID: 1442974
[TBL] [Abstract][Full Text] [Related]
5. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
[TBL] [Abstract][Full Text] [Related]
6. Histopathological and histochemical changes in the cervix uteri under contraceptive pills.
El Hakim SM; Abdin FH; Kandil O
Egypt Popul Fam Plann Rev; 1976 Dec; 10(2):20-33. PubMed ID: 12308408
[TBL] [Abstract][Full Text] [Related]
7. Modulatory influence of the oral contraceptive pill, Ovral, on 3-methylcholanthrene-induced carcinogenesis in the uterus of mouse.
Chhabra SK; Kaur S; Rao AR
Oncology; 1995; 52(1):32-4. PubMed ID: 7800339
[TBL] [Abstract][Full Text] [Related]
8. Comparative studies of the ethynyl estrogens used in oral contraceptives. III. Effect on plasma gonadotropins.
Goldzieher JW; de la Peña A; Chenault CB; Cervantes A
Am J Obstet Gynecol; 1975 Jul; 122(5):625-36. PubMed ID: 1146928
[TBL] [Abstract][Full Text] [Related]
9. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
[TBL] [Abstract][Full Text] [Related]
10. Serum vitamin A and retinol-binding protein in malnourished women treated with oral contraceptives: effects of estrogen dose and duration of treatment.
Mohan Ram M; Bamji MS
Am J Obstet Gynecol; 1979 Oct; 135(4):470-2. PubMed ID: 573554
[TBL] [Abstract][Full Text] [Related]
11. A quantitative study of the pregnancy zone protein in sera of woman taking oral contraceptives.
Damber MG; von Schoultz B; Solheim F; Stigbrand T
Am J Obstet Gynecol; 1976 Feb; 124(3):289-92. PubMed ID: 55075
[TBL] [Abstract][Full Text] [Related]
12. Fertility regulation in nursing women: V. Long-term influence of a low-dose combined oral contraceptive initiated at day 90 postpartum upon lactation and infant growth.
Peralta O; Díaz S; Juez G; Herreros C; Casado ME; Salvatierra AM; Miranda P; Durán E; Croxatto HB
Contraception; 1983 Jan; 27(1):27-38. PubMed ID: 6404597
[TBL] [Abstract][Full Text] [Related]
13. Factors affecting pituitary gonadotropin function in users of oral contraceptive steroids.
Scott JA; Brenner PF; Kletzky OA; Mishell DR
Am J Obstet Gynecol; 1978 Apr; 130(7):817-21. PubMed ID: 345817
[TBL] [Abstract][Full Text] [Related]
14. Effect of oral alanine loads on plasma amino acids in oral contraceptive users and control women.
Potera C; Rose DP
Am J Clin Nutr; 1978 May; 31(5):794-8. PubMed ID: 645627
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U
Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174
[TBL] [Abstract][Full Text] [Related]
16. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins.
Wiegratz I; Jung-Hoffmann C; Kuhl H
Contraception; 1995 Jun; 51(6):341-6. PubMed ID: 7554973
[TBL] [Abstract][Full Text] [Related]
17. Ovarian function during low-dose oral contraceptive use.
Egarter C; Putz M; Strohmer H; Speiser P; Wenzl R; Huber J
Contraception; 1995 Jun; 51(6):329-33. PubMed ID: 7554971
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of Norinyl 1/35 versus Lo-Ovral in Ile-Ife Nigeria.
Ayangade O; Akinyemi A
Int J Gynaecol Obstet; 1989 Oct; 30(2):165-70. PubMed ID: 2572488
[TBL] [Abstract][Full Text] [Related]
19. Ovarian function is effectively inhibited by a low-dose triphasic oral contraceptive containing ethinylestradiol and levonorgestrel.
Gaspard UJ; Dubois M; Gillain D; Franchimont P; Duvivier J
Contraception; 1984 Apr; 29(4):305-18. PubMed ID: 6430638
[TBL] [Abstract][Full Text] [Related]
20. Serum lipid studies in women using combination type of oral contraceptives.
Vaidya R; Purandare VN; Nain S; Gupta K; Rajwade N; Sheth UK
J Obstet Gynaecol India; 1979 Jun; 29(3):644-6. PubMed ID: 12335922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
